The Retardation of Myometrial Infiltration, Reduction of Uterine Contractility, and Alleviation of Generalized Hyperalgesia in Mice With Induced Adenomyosis by Levo-Tetrahydropalmatine (l-THP) and Andrographolide
Authors:
- 1 October 2011
- journal article
- review article
- Published by Springer Nature in Reproductive Sciences
- Vol. 18 (10) , 1025-1037
Abstract
Adenomyosis is a tough disease to manage nonsurgically. Levo-tetrahydropalmatine (l-THP), a known analgesic, and andrographolide, a nuclear factor kappa B (NF-κB) inhibitor, are both active ingredients extracted from Chinese medicinal herbs. We sought to determine whether treatment of l-THP, andrographolide, and valproic acid (VPA) would suppress the myometrial infiltration, improve pain behavior, and reduce uterine contractility in a mice model of adenomyosis. Adenomyosis was induced in 55 female ICR mice neonatally dosed with tamoxifen, while another 8 (group C) were dosed with solvent only. Starting from 4 weeks after birth, hotplate test was administrated to all mice every 4 weeks. At the 16th week, all mice with induced adenomyosis were randomly divided into 6 groups, each receiving different treatment for 3 weeks: low- or high-dose l-THP, andrographolide, low-dose l-THP and andrographolide jointly, VPA, and untreated. Group C received no treatment. After treatment, the hotplate test was administered and all mice were killed. The depth of myometrial infiltration of ectopic endometrium and uterine contractility were measured and compared across groups. We found that induction of adenomyosis resulted in progressive generalized hyperalgesia, along with elevated amplitude and irregularity of uterine contractions. Treatment with either l-THP, andrographolide, VPA, or l-THP and andrographolide jointly suppressed myometrial infiltration, improved generalized hyperalgesia, and reduced the amplitude and irregularity of uterine contractions. These results suggest that increased uterine contractility, in the form of increased contractile amplitude and irregularity, may contribute to dysmenorrhea in women with adenomyosis. More importantly, l-THP, andrographolide, and VPA all seem to be promising compounds for treating adenomyosis.Keywords
This publication has 63 references indexed in Scilit:
- Levo-Tetrahydropalmatine Retards the Growth of Ectopic Endometrial Implants and Alleviates Generalized Hyperalgesia in Experimentally Induced Endometriosis in RatsReproductive Sciences, 2011
- Possible roles of oxytocin receptor and vasopressin-1α receptor in the pathomechanism of dysperistalsis and dysmenorrhea in patients with adenomyosis uteriFertility and Sterility, 2010
- Acute and Chronic Effects of Oral Genistein Administration in Neonatal Mice1Biology of Reproduction, 2010
- Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritisRheumatology, 2010
- Correlation between NGF/TrkA and microvascular density in human pterygiumInternational Journal of Experimental Pathology, 2009
- Central Sensitization: A Generator of Pain Hypersensitivity by Central Neural PlasticityThe Journal of Pain, 2009
- Increased Immunoreactivity to SLIT/ROBO1 in Ovarian EndometriomasThe American Journal of Pathology, 2009
- The pathophysiology of endometriosis and adenomyosis: tissue injury and repairArchives of Gynecology and Obstetrics, 2009
- Calcitonin gene-related peptide stimulates proliferation of alveolar epithelial cellsRespiratory Research, 2009
- Prostaglandin E2 and F2α activate the FP receptor and up-regulate cyclooxygenase-2 expression via the cyclic AMP response elementMolecular and Cellular Endocrinology, 2008